Roche On Track To Supplement Relaunched Susvimo’s Label

18 Jul 2024

Having relaunched Susvimo for wet AMD, Roche now has the ocular implant under FDA review for approval in two diabetic ophthalmic indications and presented two-year data in those settings.

DME — Roche hopes to add two diabetes-related eye diseases to the Susvimo label • Source: Shutterstock

Now back on the market as a refillable ocular implant for wet age-related macular degeneration (AMD), Roche Holding AG/Genentech, Inc. ‘s Susvimo (ranibizumab injection) may be poised to add indications in diabetic macular edema (DME) and diabetic retinopathy (DR) as Roche seeks to build up the product as a complement to its blockbuster wet AMD, DME and retinal vein occlusion therapy Vabysmo (faricimab).

Initially approved in the US to treat wet AMD in 2021, the implant was pulled from the market in 2022...